TF and cancer: The overexpression of TF and its non-procoagulant isoform, alternatively spliced TF (asTF), were found both to facilitate tumor progression experimentally and to be associated with poor prognosis clinically, thus leading to worldwide studies of TF and its isoform in cancer therapy [5,6,7,8].